CMMB Stock Overview
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Chemomab Therapeutics Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.77 |
52 Week High | US$1.89 |
52 Week Low | US$0.42 |
Beta | -0.098 |
1 Month Change | 14.93% |
3 Month Change | 45.28% |
1 Year Change | -52.17% |
3 Year Change | -97.32% |
5 Year Change | n/a |
Change since IPO | -98.69% |
Recent News & Updates
Recent updates
Shareholder Returns
CMMB | US Biotechs | US Market | |
---|---|---|---|
7D | -2.4% | 0.9% | 0.4% |
1Y | -52.2% | 10.3% | 28.8% |
Return vs Industry: CMMB underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: CMMB underperformed the US Market which returned 29.5% over the past year.
Price Volatility
CMMB volatility | |
---|---|
CMMB Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMMB's share price has been volatile over the past 3 months.
Volatility Over Time: CMMB's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | n/a | Adi George | https://www.chemomab.com |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company’s lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd.
Chemomab Therapeutics Ltd. Fundamentals Summary
CMMB fundamental statistics | |
---|---|
Market cap | US$10.94m |
Earnings (TTM) | -US$24.22m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs CMMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CMMB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$24.22m |
Earnings | -US$24.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.71 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CMMB perform over the long term?
See historical performance and comparison